Opus Genetics, Inc.
IRDNasdaq
$3.27
↓ -0.3%Jul 17 close · end-of-day
Price
1Y↑ +192.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$284.1M
Enterprise Value
$225.4M
P/E
—
P/S
23.7
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$12.0M
Net Income (TTM)
-$106.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-359.1%
Net Margin
-892.4%
ROE
233.3%
ROIC
—
Debt / Equity
-0.0
Net Cash
$58.8M
Return 1Y
+180.7%
Company profile
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- CEO
- George Magrath
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 14
- Headquarters
- North Carolina
- Website
- opusgtx.com
Management & directors
- Gagnon Robert E.Chief Financial Officer
- Jayagopal AshwathChief Scientific & Dev. Ofc.
- Magrath GeorgeChief Executive Officer
- Schachle Joseph KChief Operating Officer
- Yerxa Benjamin RPresident
- Zaremba Rabourn AmyHead of Fin. Quality Assurance
Roles derived from SEC Form 4 filings.
Earnings
IRD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.2M↓ -50.6%
Diluted EPS-$0.75↑ +212.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $589,000.00 | $39.9M | $19.0M | $11.0M | $14.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.0M | -$22.7M | $18.2M | -$10.6M | -$62.1M | -$38.6M |
| Net income | -$24.6M | -$56.7M | $17.9M | -$10.0M | -$57.5M | -$49.6M |
| Diluted EPS | -$5.28 | -$3.82 | $0.87 | -$0.46 | -$2.15 | -$0.80 |
| Operating cash flow | -$6.8M | -$19.4M | $14.3M | -$1.1M | -$25.6M | -$35.3M |
| Free cash flow | -$6.8M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -3854.8% | 45.7% | -55.5% | -564.7% | -271.9% |
| Net margin | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.9M | $4.3M | $4.4M | $2.9M | $3.1M | $3.9M | $2.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.3M | -$8.0M | -$38.0M | -$9.9M | -$8.9M | -$8.3M | -$11.5M | -$14.4M |
| Net income | -$7.8M | -$7.5M | -$35.1M | -$8.2M | -$7.4M | -$17.5M | -$16.5M | -$65.5M |
| Diluted EPS | -$0.30 | -$0.29 | -$1.27 | -$0.24 | -$0.12 | -$0.25 | -$0.19 | -$0.75 |
| Operating cash flow | -$7.3M | -$5.1M | -$7.4M | -$9.0M | -$10.3M | -$6.2M | -$9.8M | -$12.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -748.9% | -207.1% | -884.0% | -227.2% | -309.0% | -269.9% | -296.3% | -665.9% |
| Net margin | -698.3% | -194.6% | -816.7% | -187.5% | -257.5% | -566.9% | -427.5% | -3038.2% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund | Sale | 1,700,000 | $4.35 | $7.4M | filing |
| 2026-04-23 | Magrath George· Chief Executive Officer | Sale | 9,511 | $5.22 | $49,647.42 | filing |
| 2026-04-23 | Gagnon Robert E.· Chief Financial Officer | Sale | 7,842 | $5.18 | $40,657.63 | filing |
| 2026-04-23 | Jayagopal Ashwath· Chief Scientific & Dev. Ofc. | Sale | 7,542 | $5.19 | $39,155.80 | filing |
| 2026-04-23 | YERXA BENJAMIN R· President | Sale | 7,470 | $5.24 | $39,121.14 | filing |
| 2026-04-23 | SCHACHLE JOSEPH K· Chief Operating Officer | Sale | 4,697 | $5.22 | $24,519.28 | filing |
| 2026-04-23 | Zaremba Rabourn Amy· Head of Fin. Quality Assurance | Sale | 1,641 | $5.20 | $8,539.76 | filing |
| 2026-04-20 | Ainsworth Sean | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | Rodgers Richard J | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | MANUSO JAMES S J | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | Graves Adrienne L | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | Gallagher Cam | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | Benton Susan | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-04-20 | Bennett Jean | Award | 24,367 | $0.00 | $0.00 | filing |
| 2026-03-16 | Magrath George· Chief Executive Officer | Sale | 24,438 | $5.21 | $127,326.87 | filing |
| 2026-03-16 | SCHACHLE JOSEPH K· Chief Operating Officer | Sale | 3,719 | $5.25 | $19,525.12 | filing |
| 2026-03-16 | Jayagopal Ashwath· Chief Scientific & Dev. Ofc. | Sale | 3,719 | $5.12 | $19,046.11 | filing |
| 2026-03-16 | Zaremba Rabourn Amy· Head of Fin. Quality Assurance | Sale | 2,816 | $5.25 | $14,769.92 | filing |
| 2026-02-12 | Jayagopal Ashwath· Chief Scientific & Dev. Ofc. | Tax withholding | 5,313 | $3.39 | $18,011.07 | filing |
| 2026-01-22 | Gagnon Robert E.· Chief Financial Officer | Award | 400,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | SCHACHLE JOSEPH K· Chief Operating Officer | Award | 250,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | YERXA BENJAMIN R· President | Award | 400,000 | $0.00 | $0.00 | filing |
| 2026-01-22 | Zaremba Rabourn Amy· Head of Fin. Quality Assurance | Award | 86,500 | $0.00 | $0.00 | filing |
| 2026-01-22 | Magrath George· Chief Executive Officer | Award | 483,639 | $0.00 | $0.00 | filing |
| 2026-01-22 | Jayagopal Ashwath· Chief Scientific & Dev. Ofc. | Award | 400,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.